Press Releases

Date   Headline
May 06, 2015 Cleveland BioLabs Reports First Quarter 2015 Financial Results and Development Progress
May 05, 2015 Cleveland BioLabs Announces Appointment of Biotechnology Industry Veteran, Langdon Miller, MD, as President and Chief Medical Officer
Apr 30, 2015 Cleveland BioLabs to Report First Quarter 2015 Financial Results on May 6
Apr 29, 2015 Cleveland BioLabs Enters Into Agreement to Raise Up to $4 Million Through Sales of Equity Stake in Incuron Joint Venture
Apr 27, 2015 Cleveland BioLabs and Roswell Park Cancer Institute Announce Award of Department of Defense Breast Cancer Research Program Breakthrough Grant for Entolimod
Apr 22, 2015 Cleveland BioLabs Announces Acceptance of Entolimod Phase 1 Study Findings for Poster Presentation at ASCO
Apr 14, 2015 Cleveland BioLabs Receives Funding Recommendation From Department of Defense for Additional Development Proposal for Entolimod (CBLB502) as a Medical Radiation Countermeasure
Apr 02, 2015 Cleveland BioLabs Announces New U.S. Composition of Matter Patent for CBLB612
Mar 16, 2015 Cleveland BioLabs Announces Completion of Dosing in Phase 1 Study of CBLB612 in Russian Federation
Mar 02, 2015 Cleveland BioLabs and Incuron Announce Growth of Curaxin CBL0137 Patent Portfolio With U.S. Composition of Matter Patent
Feb 24, 2015 Cleveland BioLabs Reports Fourth Quarter and Fiscal 2014 Financial Results and Development Progress
Feb 23, 2015 Cleveland BioLabs to Host Fourth Quarter and Fiscal Year 2014 Earnings Conference Call and Webcast Live on Tuesday, February 24, 2015
Feb 18, 2015 Cleveland BioLabs Announces Receipt of Letter From NASDAQ Confirming Compliance With Minimum Bid Price Requirement
Feb 17, 2015 Cleveland BioLabs to Report Fourth Quarter and Fiscal Year 2014 Financial Results on February 24
Feb 11, 2015 Cleveland BioLabs Announces Expansion of Entolimod Patent Portfolio With New Composition of Matter Patents
You are now leaving this website. If you would like to continue, click Continue.
CancelContinue